Telomir Pharmaceuticals (TELO) announced its participation in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has scheduled a full week of BIO One-on-One Partnering meetings to explore strategic collaborations, licensing opportunities, and potential M&A transactions. Telomir is actively preparing to submit an Investigational New Drug application by the end of this year for its lead candidate, Telomir-1-a novel small molecule designed to elongate telomeres, regenerate cells, and reverse core mechanisms of biological aging. The Company is gearing up for its pre-IND meeting with the FDA, with the goal of initiating first-in-human dosing in the first half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELO:
- Telomir Pharmaceuticals Joins BIO Convention for Partnerships
- Telomir Pharmaceuticals announces preclinical findings on Telomir-1
- Telomir Pharmaceuticals Announces Promising Preclinical Results
- Telomir Pharmaceuticals Appoints New Chief Financial Officer
- Telomir Pharmaceuticals announces $3M in equity financing